English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/214596
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Gentamicin as Empirical Treatment in Hemodialysis Patients: Safety, Pharmacokinetics, and Pharmacodynamics

AuthorsGuisado‐Gil, Ana B.; Herrera‐Hidalgo, Laura; Santos-Rubio, María D.; Gil‐Sacaluga, Luis; Molina Gil-Bermejo, José; Lepe, José A.; Camacho‐Martínez, Pedro; Gil-Navarro, M. V.
KeywordsDrug administration schedule
Drug‐related side effects and adverse reaction
Gentamicin
Hemodialysis
Pharmacokinetics
Issue DateDec-2019
PublisherJohn Wiley & Sons
CitationTherapeutic Apheresis and Dialysis 23(6): 550-555 (2019)
AbstractThe aim of this study was to describe the safety profile and pharmacokinetic/pharmacodynamic parameters in end‐stage renal disease patients who received gentamicin as empirical treatment in catheter‐related bacteremia when they showed infection signs, regardless of the timing of the next HD. Patients received gentamicin 3 mg/kg before blood culture extraction when they showed infection signs and regardless of the timing of next hemodialysis session. Serum concentrations were collected after the gentamicin administration (peak level) and before the next HD (trough level). Toxicities and adverse drug events were registered. The main pharmacokinetic/pharmacodynamic goal for Gram‐negative infections was peak:minimum inhibitory concentration (MIC) ≥10. Sixteen patients were included. Nephrotoxicity was not assessed in this population, and no ototoxicity was found. According to microbial isolation and gentamicin susceptibility, the value of peak:MIC was 5.4 ± 2.0. The administration of gentamicin in these conditions was safe. Estimated pharmacokinetic values were consistent with previous studies and appropriate according to peak:MIC goal for Gram‐negative organisms with MIC ≤1 mg/L.
Publisher version (URL)http://dx.doi.org/10.1111/1744-9987.12810
URIhttp://hdl.handle.net/10261/214596
DOIhttp://dx.doi.org/10.1111/1744-9987.12810
Identifiersdoi: 10.1111/1744-9987.12810
issn:: 1744-9979
e-issn:: 1744-9987
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.